Abstract 1864P
Background
Globally, more than 1.3 mio adolescents and young adults (AYAs) are diagnosed with cancer each year. Long-term survival has increased due to improved cancer therapy; however, a potential side effect is reduced fertility. Despite development in fertility preservation uncertainty regarding future fertility is still of major concern to the AYAs. The aim of this study was to identify to what extent nulliparous, female AYAs with cancer have children after cancer treatment compared to nulliparous female AYAs without cancer.
Methods
This is a national register study based on the Danish National Assisted Reproductive Technology-Couple cohort including female AYAs diagnosed with cancer when aged 18-39 from 1978–2016. According to diagnosis onset, the female AYAs with cancer were randomly age-matched with 60 female AYAs without cancer (comparison group: CG). Study participants were followed until end of study, death, or migration (31/12-2017). Death was incorporated as a competing risk in all analyses. Hazard Ratio (HR) were calculated, comparing the female AYAs with cancer with the CG. HR was adjusted for time of diagnosis, immigration status, marital status, and educational level.
Results
33.3% of AYAs with cancer had at least one child after cancer treatment vs. 40% in the CG. Female AYAs with malignant melanoma had solely a higher HR of having children after cancer treatment compared to the CG. Female AYAs with leukaemia, breast and CNS cancer had the lowest HR of having children after cancer treatment, especially in the age interval 32-39 years. Table: 1864P
N (%) | ≥ 1 child after cancer N (%) | Adjusted HR (95% CI)* | |||
18-25 y | 26-31 y | 32-39 y | |||
All | 7519 (100) | 2505 (33.3) | 0.77 (0.72-0.82) | 0.65 (0.61-0.69) | 0.59 (0.52-0.67) |
Gyn cancer | 1773 (23.6) | 435 (24.5) | 0.49 (0.42-0.58) | 0.44 (0.38-0.50) | 0.39 (0.29-0.52) |
Breast cancer | 1115 (14.8) | 179 (16.1) | 0.63 (0.42-0.95) | 0.46 (0.37-0.56) | 0.35 (0.26-0.48) |
Mal melanoma | 1960 (26.1) | 1071 (54.6) | 1.02 (0.93-1.12) | 1.03 (0.93-1.13) | 1.13 (0.92-1.39) |
CNS cancer | 303 (4.0) | 65 (21.5) | 0.70 (0.51-0.97) | 0.40 (0.26-0.61) | 0.25 (0.06-0.97) |
Leukaemia | 258 (3.4) | 37 (14.3) | 0.39 (0.26-0.57) | 0.25 (0.09-0.65) | 0.41 (0.13-1.26) |
Lymphoma | 278 (3.7) | 78 (28.1) | 0.63 (0.47-0.85) | 0.48 (0.30-0.75) | 0.76 (0.32-1.84) |
CG | 499,616 | 199,861 (40.0) | 1 | 1 | 1 |
*Adjusted analysis is based on complete case sample, N=6275. Approximately 16% (6275/7519) is excluded in the adjusted analysis due to missing data.
Conclusions
A third of nulliparous, female AYAs with cancer had at least one child after cancer which is lower than for female AYAs without cancer. The HR for having children after cancer decrease with increased age being lowest in female AYAs with leukaemia, breast- and CNS cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2018P - Novel nomogram based on the expression of DLL3 and PD-L1 for predicting the prognosis of small cell lung cancer patients
Presenter: Jun Zhao
Session: Poster session 05
2019P - Analysis of lung immune prognostic index (LIPI) score in a small cell lung cancer carcinoma (SCLC) cohort, supporting its prognostic use and investigating its predictive potential
Presenter: Mónica Esteban García
Session: Poster session 05
2020P - Circulating micro RNAs (cmiRNAs) as treatment outcome predictors in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab plus carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2021P - Cell-free (cf) DNA as predictive biomarker (B) of treatment outcome in extensive small cell lung cancer (eSCLC) patients (pts) receiving atezolizumab, carboplatin and etoposide (ACE): CATS/ML43257 study
Presenter: Giulia Pasello
Session: Poster session 05
2022P - ALBA project: Prognostic impact of laterality in small cell lung cancer
Presenter: Lorenza Landi
Session: Poster session 05
2024P - Supportive measures to control myelosuppression and costs for patients with SCLC with lurbinectedin, CAV or topotecan with or without trilaciclib: A review on the basis of clinical trials
Presenter: Manuel Dómine
Session: Poster session 05
2025P - Stratified control study of neuroendocrine differentiation and potential clinicopathologic markers
Presenter: Li Liu
Session: Poster session 05
2026P - Small cell lung cancer (SCLC) in the KBP-2020-CPHG cohort and comparison with 2000 and 2010
Presenter: Lionel Falchero
Session: Poster session 05
2027P - Immune checkpoint inhibitors in the treatment of small cell lung cancer: A systematic review and meta-analysis
Presenter: Patsy Lee
Session: Poster session 05